graphites-homaccord - krople doustne, roztwór
biologische heilmittel heel gmbh - calcium,graphites d10,graphites d10,graphites d10,calcium,calcium - krople doustne, roztwór - -
graphite
sharda cropchem ltd._x000d_ prime business park dashrathlal joshi road, vile parle (west), 400 056 mumbai, republika indii - protiokonazol - 125 g, _x000d_ tebukonazol - 125 g - fungicyd
graphites 3ch, 4ch, 5ch, 7ch, 9ch, 12ch, 15ch, 30ch, 200ch, 6k, 12k, 30k, 200k, 1mk, 10mk, 100mk granulki; granulki w pojemniku jednodawkowym; krople doustne, roztwór
boiron sa - granulki; granulki w pojemniku jednodawkowym; krople doustne, roztwór - 3ch, 4ch, 5ch, 7ch, 9ch, 12ch, 15ch, 30ch, 200ch, 6k, 12k, 30k, 200k, 1mk, 10mk, 100mk
alvia zaparcia - syrop
zakład farmaceutyczny "amara" sp. z o.o. - bryonia + lycopodium clavatum + strychnos nux - vomica ferm + graphites d10 + lycopodium clavatum + sepia officinalis d1000 + taraxacum officinale d3 + bryonia + strychnos nux - vomica ferm - syrop - -
moxifloxacin aurovitas 400 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - moxifloxacinum - tabletki powlekane - 400 mg
no-ibs 60 mg kapsułki twarde
adamed pharma s.a. - alverini citras - kapsułki twarde - 60 mg
moxinea 400 mg tabletki powlekane
solinea sp. z o.o. sp.k. - moxifloxacinum - tabletki powlekane - 400 mg
floxamic 400 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - moxifloxacinum - tabletki powlekane - 400 mg
no-ibs 120 mg kapsułki twarde
adamed pharma s.a. - alverini citras - kapsułki twarde - 120 mg
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - zapalenie stawów, reumatoidalne - leki immunosupresyjne - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.